Simvastatin in the treatment of asthma: potential effect on the IL-5 mediated changes in eosinophils

• Main Authors: Wan Chun Tsai, 蔡宛君
• Other Authors: J. H. S. Pang
• Format: Others
• Published: 2013
• Online Access: http://ndltd.ncl.edu.tw/handle/16885872497106973225

碩士 === 長庚大學 === 臨床醫學研究所 === 101 === Objective: To investigate the potential effect of simvastatin on reducing the recombinant human IL-5 (rhIL-5) mediated inflammation in HL-60 clone15-derived eosinophils (HL/Eos). Methods: HL/Eos was cultured in the presence or absence of rhIL-5, together with or without the pretreatment of simvastatin. Expressions of granule proteins and CCR3 were analyzed by fast green/neutral red stain, immunofluorescent stain and RT/real-time PCR. Function of CCR3 was investigated by chemotaxis assay to determine HL/Eos migration toward eotaxin. Results: Butyric acid (BA) up-regulated protein expression of granule proteins and CCR3 in HL-60 clone15 cells, indicating the differentiation toward eosinophil. IL-5 further increased CCR3 mRNA expression that was decreased by simvastatin. Furthermore, IL-5 significantly enhanced the chemotaxis of HL/Eos toward eotaxin that was also reduced by simvastatin. The effects of simvastatin could be partially reversed by mevalonate. Conclusion: Pretreated simvastatin could inhibit IL-5-induced granule proteins and CCR3 expression and eotaxin-induced chemotaxis of HL/Eos. Whether the act of simvastatin is through blocking the synthesis pathway of mevalonate needs further studies.